Reported Saturday, Takeda's Phase 3 Latitude PsO Data Shows Once-Daily Zasocitinib Achieves 71.4% sPGA 0/1 Response Versus 10.7% For Placebo And 32.1% For Apremilast At Week 16

Takeda's Phase 3 clinical trial for zasocitinib in treating plaque psoriasis reported that 71.4% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16, compared to 10.7% for placebo and 32.1% for apremilast. The trial also noted a significantly greater PASI 75 response rate as early as week 4, with a safety profile consistent with previous Phase 2b studies and no new safety signals identified.